Cite
HARVARD Citation
Goss, G. et al. (n.d.). Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet oncology. 17 (12), pp. 1643-1652. [Online].